Teva Pharmaceutical Industries (TEVA) investor relations material

Corporate strategy and capital deployment

• Recent deals with Royalty Pharma, Blackstone, and Abingworth provide funding to accelerate late-stage pipeline programs, enabling faster drug development and risk-sharing.

• These partnerships allow for unconstrained speed in advancing five key programs, aiming for a new drug or indication launch each year through 2027.

• The approach is designed to maximize value by expediting launches, with the value of acceleration outweighing the costs of these deals.

Pipeline and clinical development

• Five regulatory submissions are planned over the next five years, with launches for ecopipam, olanzapine LAI, and DARI targeted for 2027.

• The anti-IL-15 program for vitiligo is positioned as a potent, long-acting, and convenient systemic therapy, with proof-of-concept data expected from a 24-week phase I study.

• The celiac disease program leverages similar mechanisms as vitiligo, with strong preclinical and biomarker data supporting efficacy; a key proof-of-concept study will read out in the second half of the year.

• The TL1A program (duvakitug) has shown strong induction and maintenance data in both Crohn’s and ulcerative colitis, with phase III studies ahead of schedule and a focus on monotherapy and future combination therapies.

• The oral alpha-synuclein agent emrusolmin is undergoing a phase II futility analysis in a rapidly progressing neurological disease, with hopes for accelerated approval if successful.

R&D focus and generics strategy

• R&D integrates generics, biosimilars, and innovative medicines, leveraging synergies in device and formulation expertise across all areas.

• The generics business is now a smaller part of the portfolio, with selective investment and a focus on opportunities like GLP-1 generics, where early approval has validated the approach.

• The company avoided heavy investment in GLP-1 innovation, instead capitalizing on generics, which is seen as a strategic success.